Page 1

February 10 , 2021 REZOLUTE Rezolute Reports Second Quarter Fiscal 2021 Financial Results REDWOOD CITY , Calif . , Feb. 10 , 2021 ( GLOBE NEWSWIRE ) -- Rezolute , Inc. ( Nasdaq : RZLT ) , today announced its financial results for the quarter ended December 31 , 2020 . Recent Business Highlights • Phase 2b study of RZ358 continues to enroll congenital hyperinsulinism ( HI ) patients worldwide - The RIZE Phase 2b study of RZ358 for the treatment of congenital HI continues to enroll patients , with study completion expected in the second half of 2021. RZ358 is an allosteric modulator of the insulin receptor being developed as a treatment for all forms of congenital HI . • Initiation of Phase 1 study of RZ402 - In January 2021 , Rezolute announced initiation of dosing in a Phase 1 clinical study of oral plasma kallikrein inhibitor RZ402 in healthy volunteers . RZ402 is a potential first - in - class therapy being investigated as a once - daily oral treatment for diabetic macular edema . Study completion is expected in the first half of 2021 . Second Quarter Fiscal 2021 Financial Results • Net loss was $ 7.1 million , or $ 0.88 per share , for the second quarter of fiscal 2021 compared to net loss of $ 6.7 million , or $ 1.14 per share , for the same period in fiscal 2020 . • Cash and cash equivalents totaled $ 37.0 million as of December 31 , 2020. This includes $ 37.5 million in net proceeds from an October 2020 private placement financing . About Rezolute , Inc. Rezolute is advancing targeted therapies for rare , metabolic , and life - threatening diseases . Its lead product candidate , RZ358 , is in Phase 2b development as a potential treatment for congenital hyperinsulinism ( HI ) , a rare pediatric endocrine disorder . Its pipeline also includes RZ402 , an orally available plasma kallikrein inhibitor in Phase 1 development as a potential treatment for diabetic macular edema . For more information , visit www.rezolutebio.com or follow us on Twitter . Forward - Looking Statements This release , like many written and oral communications presented by Rezolute , Inc. and our authorized officers , may contain certain forward - looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 , as amended . We intend such forward - looking statements to be covered by the safe harbor provisions for forward - looking statements contained in the Private Securities Litigation Reform Act of 1995 and are